{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:06:06Z","timestamp":1790060766711,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Sickle cell disease (SCD) predominantly affects individuals of African descent and is characterized by frequent painful vaso-occlusive crises, often requiring opioid management. With the opioid epidemic raising concerns about opioid overdose, this study examines in-hospital outcomes among SCD and non-SCD patients hospitalized for opioid overdose. Using the National Inpatient Sample (NIS) from 2016 to 2021, we analyzed 479,175 opioid overdose hospitalizations, including 1,315 (0.3%) with a concomitant diagnosis of SCD. Propensity score matching was used to balance demographics, comorbidities, and hospital characteristics. SCD patients were younger (45.3% aged 30\u201349 vs. 33.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), predominantly of African descent (92.1% vs. 14.1%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and more often from lower-income households (58.4% vs. 35.2%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). SCD patients had lower rates of mechanical ventilation (aOR: 0.7, 95% CI: 0.6\u20130.9) and anoxic brain injury (aOR: 0.5, 95% CI: 0.4\u20130.8) but experienced longer hospital stays and higher costs. No significant differences in in-hospital mortality were observed (aOR: 0.89, 95% CI: 0.7\u20131.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.34). These findings emphasize the need for a nuanced approach to managing SCD patients during opioid overdose hospitalizations, focusing on mitigating complications, addressing prolonged hospital stays and higher costs, and reducing healthcare disparities through tailored strategies informed by the unique needs of this population.<\/jats:p>","DOI":"10.1007\/s00277-025-06236-x","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T07:28:37Z","timestamp":1741591717000},"page":"1551-1561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis"],"prefix":"10.1007","volume":"104","author":[{"given":"Anna L.","family":"Bode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar F.","family":"Borja-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Quazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqsa","family":"Mumtaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Rizwan","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abu Baker","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"6236_CR1","unstructured":"Sickle Cell Disease (SCD)| Sickle Cell Disease (SCD)| CDC. [cited 2024 Dec 22]. Available from: https:\/\/www.cdc.gov\/sickle-cell\/index.html"},{"key":"6236_CR2","unstructured":"Thomson AM, McHugh TA, Oron AP, Teply C, Lonberg N, Vilchis Tella VM et al Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023 Aug 1 [cited 2024 Dec 22];10(8):e585\u201399. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37331373\/"},{"key":"6236_CR3","doi-asserted-by":"crossref","unstructured":"Osei MA, McGann PT (2023) Sickle cell disease: time to act on the most neglected global health problem. Lancet Haematol. Aug 1 [cited 2024 Dec 22];10(8):e558\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37331372\/","DOI":"10.1016\/S2352-3026(23)00169-2"},{"key":"6236_CR4","doi-asserted-by":"crossref","unstructured":"Hassell KL Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010 Apr [cited 2024 Dec 22];38(4 Suppl). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20331952\/","DOI":"10.1016\/j.amepre.2009.12.022"},{"key":"6236_CR5","doi-asserted-by":"crossref","unstructured":"Ballas SK Opioids and Sickle Cell Disease: From Opium to the Opioid Epidemic. J Clin Med. 2021 Feb 1 [cited 2024 Dec 22];10(3):1\u201316. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33498726\/","DOI":"10.3390\/jcm10030438"},{"key":"6236_CR6","doi-asserted-by":"crossref","unstructured":"Florence C, Luo F, Rice K (2017) The economic burden of opioid use disorder and fatal opioid overdose in the United States, Drug Alcohol Depend. 2021 Jan 1 [cited 2024 Dec 22];218. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33121867\/","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"6236_CR7","doi-asserted-by":"crossref","unstructured":"Luo F, Li M, Florence C State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose - United States, 2017. MMWR Morb Mortal Wkly Rep. 2021 Apr 16 [cited 2024 Dec 22];70(15):541\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33857070\/","DOI":"10.15585\/mmwr.mm7015a1"},{"key":"6236_CR8","doi-asserted-by":"crossref","unstructured":"Sop D, Smith W, Alsalman A, Li Wong J, Fei DY, McClish D et al (2017) Survey of Physician Perspective towards Management of Pain for Chronic Conditions in the Emergency Department. Mod Clin Med Res. Oct 11 [cited 2024 Dec 22];1(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34528027\/","DOI":"10.22606\/mcmr.2017.13002"},{"issue":"2 Suppl 1","key":"6236_CR9","first-page":"1","volume":"20","author":"CS Hill","year":"1993","unstructured":"Hill CS (1993) The barriers to adequate pain management with opioid analgesics. Semin Oncol 20(2 Suppl 1):1\u20135","journal-title":"Semin Oncol"},{"key":"6236_CR10","doi-asserted-by":"crossref","unstructured":"Pergolizzi J, B\u00f6ger RH, Budd K, Dahan A, Erdine S, Hans G et al (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. Jul [cited 2024 Dec 22];8(4):287\u2013313. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18503626\/","DOI":"10.1111\/j.1533-2500.2008.00204.x"},{"key":"6236_CR11","doi-asserted-by":"crossref","unstructured":"Morrison RS, Wallenstein S, Natale DK, Senzel RS, Huang LL (2000) We don\u2019t carry that--failure of pharmacies in predominantly nonwhite neighborhoods to stock opioid analgesics. N Engl J Med. Apr 6 [cited 2024 Dec 22];342(14):1023\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10749965\/","DOI":"10.1056\/NEJM200004063421406"},{"key":"6236_CR12","doi-asserted-by":"crossref","unstructured":"Fartoukh M, Lefort Y, Habibi A, Bachir D, Galacteros F, Godeau B et al (2010) Early intermittent noninvasive ventilation for acute chest syndrome in adults with sickle cell disease: a pilot study. Intensive Care Med. 2010 Aug [cited 2024 Dec 22];36(8):1355\u201362. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20480136\/","DOI":"10.1007\/s00134-010-1907-4"},{"key":"6236_CR13","doi-asserted-by":"crossref","unstructured":"Heilbronner C, Merckx A, Brousse V, Allali S, Hubert P, De Montalembert M et al (2018) Early Noninvasive Ventilation and Nonroutine Transfusion for Acute Chest Syndrome in Sickle Cell Disease in Children: A Descriptive Study. Pediatr Crit Care Med. 2018 May 1 [cited 2024 Dec 22];19(5):E235\u201341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29356722\/","DOI":"10.1097\/PCC.0000000000001468"},{"key":"6236_CR14","doi-asserted-by":"crossref","unstructured":"Levy M, Naudin J, Geslain G, Maroni A, Koehl B, Le Bourgeois F et al (2024) Factors associated with adverse outcome among children with sickle cell disease admitted to the pediatric intensive care unit: an observational cohort. Ann Intensive Care. 2024 Dec 1 [cited 2024 Dec 22];14(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38594419\/","DOI":"10.1186\/s13613-024-01283-5"},{"key":"6236_CR15","doi-asserted-by":"crossref","unstructured":"Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ et al (2020). Trends in Sickle Cell Disease-Related Mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020 Sep 1 [cited 2024 Dec 22] 76(3S):S28\u201336. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32928459\/","DOI":"10.1016\/j.annemergmed.2020.08.009"},{"key":"6236_CR16","unstructured":"NIS Database Documentation [cited 2024 Dec 22]. Available from: https:\/\/hcup-us.ahrq.gov\/db\/nation\/nis\/nisdbdocumentation.jsp"},{"key":"6236_CR17","unstructured":"Federal Policy for the Protection of Human Subjects (\u2018Common Rule| HHS.gov. [cited 2024 Dec 22]. Available from: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/regulations\/common-rule\/index.html"},{"key":"6236_CR18","doi-asserted-by":"crossref","unstructured":"Akindele AO, Jalkh AP, Eastmond AK, Shetty C, Rizvi SMHA, Sharaf J et al (2022). Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review. Cureus. Aug 24 [cited 2024 Dec 22];14(8). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36176876\/","DOI":"10.7759\/cureus.28337"},{"key":"6236_CR19","doi-asserted-by":"crossref","unstructured":"Jang T, Poplawska M, Cimpeanu E, Mo G, Dutta D, Lim SH (2021) Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021 Dec 1 [cited 2024 Dec 22];19(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34544432\/","DOI":"10.1186\/s12967-021-03074-z"},{"key":"6236_CR20","doi-asserted-by":"crossref","unstructured":"Diakite AA, Coulibaly Y, Dicko-Traore F, Traore B, Togo B, Dembele A et al (2009) Treatment of sickle cell pain: fostering trust and justice. JAMA. [cited 2024 Dec 22];302(22):25\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19996405\/","DOI":"10.1001\/jama.2009.1811"},{"issue":"4","key":"6236_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/082585970502100403","volume":"21","author":"E Labb\u00e9","year":"2005","unstructured":"Labb\u00e9 E, Herbert D, Haynes J (2005) Physicians\u2019 attitude and practices in sickle cell disease pain management. J Palliat Care 21(4):246\u2013251","journal-title":"J Palliat Care"},{"key":"6236_CR22","doi-asserted-by":"crossref","unstructured":"Pack-Mabien A, Labbe E, Herbert D, Haynes J (2001) Nurses\u2019 attitudes and practices in sickle cell pain management. Appl Nurs Res. [cited 2024 Dec 22];14(4):187\u201392. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11699021\/","DOI":"10.1053\/apnr.2001.26783"},{"key":"6236_CR23","doi-asserted-by":"crossref","unstructured":"Shapiro BS, Benjamin LJ, Payne R, Heidrich G (1997) Sickle cell-related pain: perceptions of medical practitioners. J Pain Symptom Manage. 1997 Sep [cited 2024 Dec 22];14(3):168\u201374. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9291703\/","DOI":"10.1016\/S0885-3924(97)00019-5"},{"key":"6236_CR24","doi-asserted-by":"crossref","unstructured":"Waldrop RD, Mandry C (1995) Health professional perceptions of opioid dependence among patients with pain. Am J Emerg Med. [cited 2024 Dec 22];13(5):529\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7662056\/","DOI":"10.1016\/0735-6757(95)90163-9"},{"key":"6236_CR25","doi-asserted-by":"crossref","unstructured":"Kang HA, Wang B, Barner JC, Ataga KI, Mignacca RC, Chang A et al (2024) Opioid Prescribing and Outcomes in Patients With Sickle Cell Disease Post-2016 CDC Guideline. JAMA Intern Med. May 6 [cited 2024 Dec 22];184(5):510\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38466269\/","DOI":"10.1001\/jamainternmed.2023.8538"},{"key":"6236_CR26","doi-asserted-by":"crossref","unstructured":"Ruta NS, Ballas SK (2016) The Opioid Drug Epidemic and Sickle Cell Disease: Guilt by Association. Pain Med. Oct 1 [cited 2024 Dec 22];17(10):1793\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27152018\/","DOI":"10.1093\/pm\/pnw074"},{"key":"6236_CR27","doi-asserted-by":"crossref","unstructured":"Ballas SK (2021) Opioids are not a major cause of death of patients with sickle cell disease. Ann Hematol. May 1 [cited 2024 Dec 22];100(5):1133\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33758998\/","DOI":"10.1007\/s00277-021-04502-2"},{"key":"6236_CR28","doi-asserted-by":"crossref","unstructured":"Darbari DS, Neely M, Van Den Anker J, Rana S (2011) Increased clearance of morphine in sickle cell disease: implications for pain management. J Pain. May [cited 2024 Dec 22];12(5):531\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21277838\/","DOI":"10.1016\/j.jpain.2010.10.012"},{"key":"6236_CR29","doi-asserted-by":"crossref","unstructured":"Dampier CD, Setty BNY, Logan J, Ioli JG, Dean R (1995) Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease. J Pediatr. [cited 2024 Dec 22];126(3):461\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7869211\/","DOI":"10.1016\/S0022-3476(95)70472-8"},{"issue":"Supplement 1","key":"6236_CR30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2021-145658","volume":"138","author":"M Khan","year":"2021","unstructured":"Khan M, Han J, Saraf SL, Molokie RE (2021) Naloxone Use for opioid reversal in patients with Sickle Cell Disease. Blood 138(Supplement 1):2038\u20132038","journal-title":"Blood"},{"key":"6236_CR31","doi-asserted-by":"crossref","unstructured":"Naik RP, Streiff MB, Lanzkron S (2013) Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis. 2013 Apr [cited 2024 Dec 22] 35(3):352\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23435703\/","DOI":"10.1007\/s11239-013-0895-y"},{"key":"6236_CR32","doi-asserted-by":"crossref","unstructured":"Cappellini MD (2007) Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program. [cited 2024 Dec 22];74\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18024612\/","DOI":"10.1182\/asheducation-2007.1.74"},{"issue":"Supplement 1","key":"6236_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2021-152850","volume":"138","author":"L Mucalo","year":"2021","unstructured":"Mucalo L, Brandow AM, Singh A (2021) Opioid-related mortality for individuals with sickle cell disease remains low with no significant increase during 2013\u20132019. Blood 138(Supplement 1):124\u2013124","journal-title":"Blood"},{"key":"6236_CR34","doi-asserted-by":"crossref","unstructured":"Hood AM, Crosby LE, Hanson E, Shook LM, Lebensburger JD, Madan-Swain A et al (2022 )The influence of perceived racial bias and health-related stigma on quality of life among children with sickle cell disease. Ethn Health. [cited 2024 Dec 22];27(4):833\u201346. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32896156\/","DOI":"10.1080\/13557858.2020.1817340"},{"key":"6236_CR35","doi-asserted-by":"crossref","unstructured":"Green CR, Anderson KO, Baker TA, Campbell LC, Decker S, Fillingim RB et al (2003) The unequal burden of pain: confronting racial and ethnic disparities in pain. Pain Med. [cited 2024 Dec 22];4(3):277\u201394. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/12974827\/","DOI":"10.1046\/j.1526-4637.2003.03034.x"},{"key":"6236_CR36","doi-asserted-by":"crossref","unstructured":"Telfair J, Myers J, Drezner S (1998) Does race influence the provision of care to persons with sickle cell disease? Perceptions of multidisciplinary providers. J Health Care Poor Underserved. [cited 2024 Dec 22];9(2):184\u201395. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10073202\/","DOI":"10.1353\/hpu.2010.0127"},{"key":"6236_CR37","doi-asserted-by":"crossref","unstructured":"Wahab S, Kelly K, Klingler M, Pirovic A, Futch K, Rennie C et al (2024) Impact of Race, Socioeconomic Status, and Geography on Healthcare Outcomes for Children With Sickle Cell Disease in the United States: A Scoping Review. Cureus. 2024 Mar 13 [cited 2024 Dec 22];16(3). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38618364\/","DOI":"10.7759\/cureus.56089"},{"key":"6236_CR38","doi-asserted-by":"crossref","unstructured":"Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH et al (2014) Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. Sep 10 [cited 2024 Dec 22];312(10):1033\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25203083\/","DOI":"10.1001\/jama.2014.10517"},{"key":"6236_CR39","doi-asserted-by":"publisher","unstructured":"Brandow AM, Carroll CP, Creary S, Edwards-Elliott R, Glassberg J, Hurley RW et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. Jun 23 [cited 2024 Dec 22];4(12):2656\u2013701. Available from: https:\/\/doi.org\/10.1182\/bloodadvances.2020001851","DOI":"10.1182\/bloodadvances.2020001851"},{"key":"6236_CR40","doi-asserted-by":"crossref","unstructured":"Crain SM, Shen KF (2000) Antagonists of excitatory opioid receptor functions enhance morphine\u2019s analgesic potency and attenuate opioid tolerance\/dependence liability. Pain. 2000 Feb 1 [cited 2024 Dec 22];84(2\u20133):121\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/10666516\/","DOI":"10.1016\/S0304-3959(99)00223-7"},{"key":"6236_CR41","doi-asserted-by":"crossref","unstructured":"Crain SM, Shen KF (2001) Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res. Jan 5 [cited 2024 Dec 22];888(1):75\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/11146054\/","DOI":"10.1016\/S0006-8993(00)03010-9"},{"key":"6236_CR42","doi-asserted-by":"crossref","unstructured":"Crain SM, Shen KF (1998) Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci. Sep 1 [cited 2024 Dec 22];19(9):358\u201365. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9786023\/","DOI":"10.1016\/S0165-6147(98)01241-3"},{"key":"6236_CR43","doi-asserted-by":"crossref","unstructured":"Crain SM, Shen KEF, S A (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance\/dependence during chronic cotreatment. Proc Natl Acad Sci U. Nov 7 [cited 2024 Dec 22];92(23):10540\u20134. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7479836\/","DOI":"10.1073\/pnas.92.23.10540"},{"key":"6236_CR44","doi-asserted-by":"crossref","unstructured":"Koch J, Manworren R, Clark L, Quinn CT, Buchanan GR, Rogers ZR (2008) Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis. Am J Hematol. Sep [cited 2024 Dec 22];83(9):728\u201331. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18543345\/","DOI":"10.1002\/ajh.21213"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06236-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T10:11:10Z","timestamp":1745575870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06236-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6236"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06236-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}